Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 10 01:14PM ET
0.6742
Dollar change
+0.1463
Percentage change
27.71
%
IndexRUT P/E- EPS (ttm)-0.09 Insider Own31.28% Shs Outstand168.51M Perf Week82.31%
Market Cap114.98M Forward P/E- EPS next Y-0.49 Insider Trans-1.25% Shs Float117.21M Perf Month9.18%
Income-16.76M PEG- EPS next Q-0.16 Inst Own35.58% Short Float11.04% Perf Quarter-1.98%
Sales1.12M P/S102.66 EPS this Y77.49% Inst Trans-1.18% Short Ratio5.10 Perf Half Y-35.79%
Book/sh0.35 P/B1.91 EPS next Y-282.93% ROA-9.54% Short Interest12.94M Perf Year-23.41%
Cash/sh0.79 P/C0.85 EPS next 5Y- ROE-26.35% 52W Range0.26 - 1.60 Perf YTD-19.59%
Dividend Est.- P/FCF- EPS past 5Y73.95% ROI-12.27% 52W High-57.86% Beta0.32
Dividend TTM- Quick Ratio4.80 Sales past 5Y-20.00% Gross Margin20.48% 52W Low158.12% ATR (14)0.07
Dividend Ex-Date- Current Ratio4.89 EPS Y/Y TTM89.36% Oper. Margin-11654.94% RSI (14)70.33 Volatility13.80% 17.67%
Employees93 Debt/Eq1.31 Sales Y/Y TTM- Profit Margin-1492.34% Recom1.33 Target Price2.68
Option/ShortYes / Yes LT Debt/Eq1.29 EPS Q/Q-1461.54% Payout- Rel Volume7.02 Prev Close0.53
Sales Surprise-66.79% EPS Surprise-5.02% Sales Q/Q- EarningsNov 13 BMO Avg Volume2.54M Price0.67
SMA2067.47% SMA5038.02% SMA200-16.75% Trades Volume10,614,206 Change27.71%
Date Action Analyst Rating Change Price Target Change
Dec-12-23Downgrade B. Riley Securities Buy → Neutral $3 → $1
Aug-30-23Resumed B. Riley Securities Buy $3
Dec-22-22Initiated Cantor Fitzgerald Overweight $3
Dec-12-22Initiated Piper Sandler Overweight $3
Dec-23-19Initiated Oppenheimer Outperform $20
Dec-18-19Initiated ROTH Capital Buy $20
Dec-09-19Upgrade Citigroup Neutral → Buy $16 → $20
Dec-05-19Initiated B. Riley FBR Buy
Jun-07-19Initiated Stifel Buy $27
Jun-05-19Initiated Cowen Outperform
Dec-04-24 08:00AM
08:00AM
Dec-03-24 04:05PM
Nov-26-24 08:00AM
Nov-14-24 08:00AM
02:06AM Loading…
02:06AM
Nov-13-24 06:26AM
06:13AM
06:07AM
06:01AM
Nov-07-24 11:36AM
Nov-01-24 04:05PM
Oct-24-24 08:00AM
Oct-01-24 04:05PM
Sep-03-24 04:05PM
08:00AM Loading…
Aug-28-24 08:00AM
Aug-08-24 06:13AM
06:01AM
Aug-01-24 04:05PM
Jul-30-24 08:00AM
Jun-27-24 06:30AM
Jun-03-24 04:05PM
May-29-24 04:30PM
May-13-24 08:00AM
May-09-24 03:59PM
11:52AM
07:29AM
06:30AM
May-08-24 11:10AM
03:14AM
10:54AM Loading…
May-07-24 10:54AM
06:07AM
06:01AM
May-01-24 04:05PM
Apr-30-24 09:32AM
08:00AM
Apr-29-24 11:19AM
06:47AM
06:30AM
Apr-02-24 04:05PM
Apr-01-24 08:00AM
Mar-22-24 12:47PM
Mar-21-24 10:09PM
10:53AM
09:11AM
06:01AM
Mar-12-24 08:00AM
Mar-01-24 04:05PM
Feb-01-24 04:05PM
Dec-09-23 12:00PM
Dec-04-23 04:05PM
Nov-10-23 03:46PM
08:00AM
01:48AM
Nov-09-23 09:29AM
06:01AM
Nov-02-23 08:00AM
Nov-01-23 04:05PM
Oct-31-23 08:00AM
Oct-18-23 08:00AM
Oct-02-23 04:05PM
Sep-19-23 08:00AM
Sep-06-23 08:00AM
Sep-05-23 08:00AM
Sep-01-23 04:05PM
Aug-15-23 10:53AM
Aug-10-23 06:38AM
06:05AM
Aug-08-23 04:05PM
Aug-03-23 08:00AM
Aug-02-23 08:01AM
Jun-30-23 04:05PM
Jun-14-23 06:26AM
Jun-13-23 08:00AM
Jun-02-23 04:05PM
May-16-23 04:01PM
08:30AM
May-15-23 04:44AM
May-04-23 06:12AM
06:05AM
Apr-26-23 12:32PM
08:01AM
Apr-12-23 08:00AM
Apr-04-23 04:05PM
Mar-24-23 07:36AM
Mar-21-23 06:05AM
Mar-07-23 08:01AM
Mar-02-23 04:05PM
Jan-31-23 12:00PM
Dec-12-22 08:30AM
Dec-07-22 08:43AM
Dec-06-22 06:26PM
Nov-30-22 08:05AM
Nov-29-22 04:01PM
Nov-17-22 09:51AM
Nov-08-22 08:00AM
Nov-04-22 04:05PM
Nov-03-22 06:05AM
Oct-26-22 08:00AM
Oct-20-22 08:00AM
X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. Its clinical candidate is mavorixafor. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ragan PaulaPresident and CEONov 15 '24Sale0.3931,89712,583993,919Nov 19 04:31 PM
Ragan PaulaOfficerNov 15 '24Proposed Sale0.4131,89713,078Nov 15 04:12 PM
Ragan PaulaPresident and CEOOct 15 '24Sale0.5631,89717,9261,025,816Oct 16 04:54 PM
Ragan PaulaOfficerOct 15 '24Proposed Sale0.5631,89717,862Oct 15 04:07 PM
Mostafa Adam S.Chief Financial OfficerOct 07 '24Sale0.55230,645126,9010Oct 08 04:44 PM
Baldry MarkChief Commercial OfficerOct 07 '24Sale0.5811,1276,50648,509Oct 08 04:44 PM
Ragan PaulaPresident and CEOOct 07 '24Sale0.55239,436131,5221,057,713Oct 08 04:44 PM
DiBiase MaryChief Operating OfficerOct 07 '24Sale0.5767,69538,329452,060Oct 08 04:44 PM
Taveras ArthurChief Scientific OfficerOct 07 '24Sale0.5676,92043,306388,026Oct 08 04:44 PM
DiBiase MaryOfficerOct 07 '24Proposed Sale0.6467,69543,095Oct 07 04:14 PM
Mostafa Adam S.OfficerOct 07 '24Proposed Sale0.64230,645146,829Oct 07 04:13 PM
Ragan PaulaOfficerOct 07 '24Proposed Sale0.64239,436152,425Oct 07 04:09 PM
DiBiase MaryChief Operating OfficerSep 09 '24Sale0.662,6421,738289,110Sep 11 04:01 PM
DiBiase MaryOfficerSep 09 '24Proposed Sale0.652,6421,728Sep 09 04:06 PM
Taveras ArthurChief Scientific OfficerMar 11 '24Sale0.8814,23512,552234,301Mar 11 05:20 PM
Ragan PaulaPresident and CEOMar 11 '24Sale0.8849,67843,856765,068Mar 11 05:20 PM
Mostafa Adam S.Chief Financial OfficerMar 11 '24Sale0.8852,50046,3470Mar 11 05:19 PM
DiBiase MaryChief Operating OfficerMar 11 '24Sale0.8815,40913,591291,752Mar 11 05:19 PM
DiBiase MaryChief Operating OfficerFeb 12 '24Sale1.013,6833,709307,161Feb 12 05:23 PM
Taveras ArthurChief Scientific OfficerFeb 12 '24Sale1.01787793248,536Feb 12 05:23 PM
Ragan PaulaPresident and CEOFeb 12 '24Sale1.0121,69521,892814,746Feb 12 05:05 PM
Mostafa Adam S.Chief Financial OfficerFeb 12 '24Sale1.0127,72127,97352,500Feb 12 05:03 PM